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Mutation allele burden remains unchanged in
chronic myelomonocytic leukaemia responding
to hypomethylating agents
Jane Merlevede1,2,*, Nathalie Droin1,2,3,*, Tingting Qin4, Kristen Meldi4, Kenichi Yoshida5, Margot Morabito1,2,
Emilie Chautard6, Didier Auboeuf7, Pierre Fenaux8, Thorsten Braun9, Raphael Itzykson8, Ste´phane de Botton1,2,
Bruno Quesnel10, The´re`se Commes11, Eric Jourdan12, William Vainchenker1,2, Olivier Bernard1,2, Noemie Pata-Merci3,
Ste´phanie Solier1,2, Velimir Gayevskiy13, Marcel E. Dinger13, Mark J. Cowley13, Dorothe´e Selimoglu-Buet1,2, Vincent Meyer14,
Franc¸ois Artiguenave14, Jean-Franc¸ois Deleuze14, Claude Preudhomme10, Michael R. Stratton15, Ludmil B. Alexandrov15,16,17,
Eric Padron18, Seishi Ogawa5, Serge Koscielny19, Maria Figueroa4 & Eric Solary1,2,20
The cytidine analogues azacytidine and 5-aza-2’-deoxycytidine (decitabine) are commonly
used to treat myelodysplastic syndromes, with or without a myeloproliferative component. It
remains unclear whether the response to these hypomethylating agents results from a cyto-
toxic or an epigenetic effect. In this study, we address this question in chronic myelomonocytic
leukaemia. We describe a comprehensive analysis of the mutational landscape of these
tumours, combining whole-exome and whole-genome sequencing. We identify an average of
14±5 somatic mutations in coding sequences of sorted monocyte DNA and the signatures of
three mutational processes. Serial sequencing demonstrates that the response to hypo-
methylating agents is associated with changes in DNA methylation and gene expression,
without any decrease in the mutation allele burden, nor prevention of new genetic alteration
occurence. Our ﬁndings indicate that cytosine analogues restore a balanced haematopoiesis
without decreasing the size of the mutated clone, arguing for a predominantly epigenetic effect.
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MML, a clonal haematopoietic malignancy that usually
occurs in the elderly, is the most frequent myelodysplastic
syndrome/myeloproliferative neoplasm1. Nonspeciﬁc
cytogenetic abnormalities are observed in 30–40% of cases2.
More than 30 candidate genes were identiﬁed to be recurrently
mutated in leukaemia cells3–13. Analysis of these recurrently
mutated genes at the single cell level in 28 CMML bone marrow
samples identiﬁed the main features of the leukaemic clone
architecture, including the accumulation of mutations in the stem
cell compartment with early clonal dominance, a low number of
subclones, and a strong advantage to the most mutated cells
with differentiation4. As in several other myeloid malignancies,
ASXL1 gene mutations demonstrated the strongest independent
negative prognostic impact14,15.
The median overall survival of CMML patients is about
30 months, one-third evolving to acute myeloid leukaemia (AML)
while the others die from the consequences of cytopenias.
Allogeneic stem cell transplantation, which is the only curative
therapy, is rarely feasible because of age. In patients ineligible for
transplantation, intensive chemotherapy results in low response
rates and short response duration2. The cytidine analogues
azacytidine (AZA) and decitabine (5-aza-20-deoxycytidine) were
approved for the treatment of CMML16. These azanucleosides
were originally described as cytotoxic drugs, but low doses
also cause DNA demethylation by inactivation of DNA
methyltransferases17,18. It remains unclear whether the response
to these drugs, which is always transient, results from a cytotoxic
or an epigenetic effect.
In this study, to tackle this issue, we completed a comprehensive
analysis of genetic alterations in CMML cells by combining
whole-exome (WES) and whole-genome sequencing (WGS). Then,
we performed sequential WES and RNA sequencing (RNA-Seq)
together with DNA methylation analyses in untreated patients and
patients treated with a hypomethylating drug. Clinical response to
cytidine analogues was associated with a dramatic decrease in
DNA methylation, which was not observed when the disease
remained stable on therapy. In responding patients, the size of the
mutated clone remained unchanged, arguing for a predominantly
epigenetic effect of these drugs.
Results
Genetic alterations in coding regions. Since it remained
uncertain whether the most frequent recurrent gene mutations
had been all identiﬁed, we performed WES of paired tumour–
control DNA from 49 CMML cases (Supplementary Figs 1 and 2,
Supplementary Tables 1 and 2). and validated 680 somatic
mutations in 515 genes by deep resequencing (Supplementary
Data 1). The average number of somatic mutations was 14±5 per
patient (range: 4–23; Fig. 1a). The most frequent alterations were
somatic nonsynonymous single-nucleotide variants (SNVs;
N¼ 515; 75.7%; Fig. 1b). Most of the 618 variants were transi-
tions (N¼ 453, 73.3%; Fig. 1c). We detected mutations affecting
an epigenetic regulator gene in 45 out of 49 (91.8%) patients, a
splicing machinery gene in 37 (75.5%) and a signal transduction
gene in 28 (59.2%). Among the 36 genes found mutated in at least
2 patients, 19 had been previously identiﬁed in the context of
CMML, validating previous screens of mutations in candidate
genes in this speciﬁc disease3–13. TET2, SRSF2 and ASXL1 were
conﬁrmed to be the most frequently mutated genes in CMML14.
Of the 17 other recurrently mutated genes, only 7 were actively
transcribed in CD14-positive19 and CD34-positive
haematopoietic cells (according to Gene Expression Omnibus at
http://www.ncbi.nlm.nih.gov/geo/). These genes include ABCC9
(ATP-binding cassette, sub-family C member 9), ASXL2
(additional sex combs-like 2), DOCK2 (dedicator of cytokinesis
protein 2), HUWE1 (HECT, UBA and WWE domain
containing 1, E3 ubiquitin protein ligase), NF1 (Neuroﬁbromin
1), PHF6 (PHD ﬁnger protein 6) and TTN (Titin). Altogether,
recurrent mutations were identiﬁed in 26 genes expressed in
haematopoietic cells (Fig. 1d). Constitutive truncating mutations
in TTN gene were recently validated as a cause of dilated
cardiomyopathy20 and the variants identiﬁed in CMML samples
were validated by an independent method. Except this very large
gene, the whole coding sequence of the 6 other genes, whose
recurrent mutation in the context of CMML had not been
described previously, was deep sequenced in an additional cohort
of 180 patients (Supplementary Table 3). Of the 229 studied
patients, the most frequently mutated gene was PHF6 (N¼ 17;
7.4%). NF1 was altered in 14 (6.1%) patients. DOCK2 and ABCC9
mutations were detected, respectively, in ﬁve samples (2.1%),
HUWE1mutations in three samples (1.3%) and ASXL2mutations
in two samples (Supplementary Table 4). On average, each
patient had 3.1 alterations (range: 1–7) among the 26 recurrently
mutated genes identiﬁed in this series. Combinations are
summarized in Supplementary Fig. 3 and relationships with
clinical and biological features in Supplementary Table 5.
We extended this analysis by performing WGS of paired
tumour–control DNA from 17 patients. Of the 8,077 somatic
variants identiﬁed (Fig. 2a, Supplementary Table 6 and
Supplementary Data 2), 207 were located in coding regions or
splice sites (11.8 per patient; Fig. 2b) and the combination of WES
and WGS identiﬁed two additional recurrently mutated genes
that are actively transcribed in haematopoietic cells, ten-eleven
translocation 3 (TET3) and proline-rich coiled-coil 2B (PRRC2B).
All these additional recurrent abnormalities may contribute to
CMML phenotype heterogeneity.
TET3 loss of function mutation. TET3 mutations are very
infrequent in haematologic diseases21,22 and were not detected in
myeloid malignancies so far23. In the two patients with a mutated
TET3 gene, the two alleles of TET2 were also mutated. We further
explored the functional consequences of TET3R148H identiﬁed
in UPN22. Genetic analyses of CD14þ cells at the single cell
level (N¼ 21) identiﬁed a complex repartition of TET2 and TET3
mutations, with TET2S1708fs being either alone or in combination
with TET3R148H, whereas TET2L1819X was detected in only
one TET3 wild-type cell (Fig. 3a). Expression of wild-type and
TET3R148H alleles in HEK293T cells (Fig. 3b) demonstrated
that TET3R148H mutation impaired the enzyme ability to
promote 5-methylcytosine hydroxylation (Fig. 3c). Since many
functional redundancies have been identiﬁed between TET2 and
TET3 dioxygenases (for review see ref. 24), future studies are
necessary to elucidate a potential cooperative interaction between
TET2 and TET3 mutated alleles in diseased cells.
Genetic alterations in non-coding regions. Further analysis of
WGS data indicated that, on average, CMML cells carried 475
(range: 27–854) somatic variants in their DNA (Fig. 2a), 6.3%
being short insertions and deletions. These variants were mostly
in intergenic (63.5%) and intronic (31.5%) regions (Fig. 2b).
Somatic SNVs (93.7%) were mostly transitions (66.3%; Fig. 2c),
and synonymous base changes represented 24.1% of the identiﬁed
variants (Fig. 2d). Our computational framework for extracting
mutational signatures25 identiﬁed the signatures of three
mutational processes (Fig. 2e). Two (signatures 1 and 5) were
previously observed26 and believed to be due to clock-like
mutational processes operative in normal somatic tissues.
Interestingly, we identiﬁed in two cases a novel mutational
signature (signature 31) characterized by C:G4T:A mutations at
CpCpC and CpCpT (mutated based underlined) and exhibiting a
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strong transcriptional strand bias (Supplementary Fig. 4). We did
not detect any recurrent alteration in non-coding regions, as
described in other tumour types27–29. We identiﬁed 21 potential
hotspot regions with at least 2 variants in distinct samples being at
most 250 bp far (Fig. 2f). Nine were in the coding sequence of
recurrently mutated genes, and 3 in non-coding regions of genes
transcribed in haematopoietic cells (PDS5A, ZFP36L2 and
NHLRC2). Finally, we detected 147 variants in promoters and 37













































































































































Figure 1 | Somatic variants in coding regions identiﬁed by whole-exome sequencing. WES was performed in 49 chronic myelomonocytic leukaemia
samples. (a) Number and type of somatic mutations identiﬁed in each patient designated as UPN, showing a majority of nonsynonymous variants. (b)
Repartition of the 680 validated somatic variants identiﬁed in the 49 patients. (c) Repartition of base changes with transitions in black and transversions in
grey. (d) Of the 36 recurrently mutated genes identiﬁed by WES, 26 are actively transcribed in CD14þ cells and CD34þ cells (according to Gene
Expression Omnibus at http://www.ncbi.nlm.nih.gov/geo/). These 26 recurrently mutated genes are classiﬁed according to their function, including
epigenetic regulation, pre-messenger RNA splicing, and signal transduction. Colours indicate the type of mutation. Two colours separated by a slash
indicate two distinct mutations in the same gene.
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Figure 2 | Somatic variants in coding and non-coding regions identiﬁed by whole-genome sequencing. WGS was performed in 17 chronic
myelomonocytic leukaemia samples (including one analysed by WES). (a) Number of somatic single-nucleotide variants and short insertions/deletions in
each patient. (b) Repartition of the 8077 somatic variants, expressed as numbers of variants per gigabase, identiﬁed across the genomic regions. Mean and
95% conﬁdence intervals (n¼ 17) are shown. (c) Repartition of base changes with transitions in black and transversions in grey. (d) Repartition of the 207
somatic variants identiﬁed in coding regions. (e) Mutational signatures extracted from whole genomic analyses. (f) Potential hotspots of mutations (two
variants less than 250bp apart) including nine in coding regions of driver genes (including TET2, ASXL1, SRSF2, CBL and NRAS), two in intronic regions of
PDS5A and NHLRC2, one in 3’UTR of ZFP36L2, six in intergenic regions and 1 in the mitochondrial chromosome. Numbers between comas indicate the
chromosome number.
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variants in permissive enhancers, of which 3 showed activity in
blood cells (Supplementary Data 3)30.
Serial whole-exome analyses. WES of sorted monocyte DNA was
repeated in 17 patients. The mean time between two analyses
was 14±8 months (range: 4–32). Six patients received supportive
care, whereas 11 were treated with either AZA (N¼ 5) or
decitabine (N¼ 6). The number of serial analyses per patient
ranged from two to ﬁve (Supplementary Fig. 1 and Table 7). The
mean duration of treatment was 21±13 months (range: 5–47).
One or two WES were performed before treatment, subsequent
analyses being performed on therapy in samples collected
immediately before the next cycle. Five of the treated patients
demonstrated a response at the time of sampling (‘responders’),
including one complete response (UPN32), three marrow
complete responses with haematological improvement and one
marrow complete response without haematological improvement
(UPN34). In the six other patients, the disease remained stable
on therapy, without haematological improvement (‘non-
responders’)18,31. In total, we performed 27 serial WES analyses.
In 17 cases, we did not detect any change in gene mutations as
compared with the previous analysis, the mutated allele burden
remaining stable in all patients but two (UPN23 and UPN47;
Fig. 4). In responding patients, hypomethylating agents did not
decrease the mutated allele burden in circulating monocytes.
In eight cases, we detected changes in the number of mutated
genes, including three untreated, three non-responders with a
stable disease and one responder (Fig. 4 and Supplementary
Fig. 5). The latter was a 74-year-old man (UPN34) with 12
somatic mutations at diagnosis who successively acquired
mutations in CNTN4 and RAD21 genes, then in KRAS, CNTN6
and PCDHGA6 genes while being in complete marrow response
without haematological improvement. The last exome analysis,
performed in acute transformation, identiﬁed an EZH2/ETV6
mutated subclone (Supplementary Fig. 5). UPN46 was analysed
ﬁrst while being untreated, showing the disappearance of a
subclone with ARID2 and NRAS mutations while another clone
with NRAS, ROBO2, FAT1 and SGSM2 mutations expanded. This
patient was subsequently treated with decitabine and responded
to treatment, without change in mutation number and allele
burden (Fig. 4c, Supplementary Fig. 5 and Fig. 6).
In one additional patient who demonstrated a long and
complete response to AZA, then progressed to AML (Methods
section), serial WGS of bone marrow mononucleated cells32 was
performed. Before AZA therapy, somatic variants in TET2, EZH2
and CBL genes were identiﬁed. In a best response sample, a
striking stability of variant allele frequency was observed. At the
time of progression, a loss of heterozygocity of mutated EZH2
was detected, together with the acquisition of a mutation in
ASXL1, and a whole loss of chromosome 7, which was conﬁrmed



































































Figure 3 | TET3–R1548H mutation inhibits 5hmC modiﬁcation. (a) Single cell analysis of TET3R1548H, TET2S1708fsX11 and TET2L1819X mutations in
sorted CD14þ cells from UPN22. (b) TET2 and TET3 gene expression measured by quantitative reverse transcriptase–PCR in HEK293T cells transfected
with the pcDNA3.1 empty vector or pcDNA3.1 encoding wild-type (TET3-WT) and R1548H TET3 (TET3-MUT). Reporter gene: RPL32. Results are related to
pcDNA3.1 control. Error bars represent mean±standard deviation of triplicates. (c) Dot blot analysis of 5-hydroxymethylcytosine (5hmC) on genomic
DNA (4-fold serial dilutions in ng) isolated from HEK293T cells transfected as in b.
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emphasizes the lack of genetic response to AZA and the
possibility to detect genetic progression on therapy, preceding
progression to acute leukaemia.
Gene expression and DNA methylation. In nine of these
patients, we performed serial RNA-Seq (Fig. 6, Supplementary
Tables 8 and 9), the ﬁrst sample being collected before treatment.
Three remained untreated, and six were treated with a
hypomethylating drug, the second sample being collected on
therapy. Of the six treated patients, three were responders, the
three others remaining on therapy with stable disease
(non-responders). We measured the effect of time on gene
expression. We noticed a strong impact of treatment in
responders, with 513 differentially expressed genes, whereas only
63 genes were differentially expressed in treated patients with
stable disease (non-responders), and none in untreated patients
(Table 1, Fig. 6a,b and Supplementary Data 4). The proportions
of signiﬁcantly differentially expressed genes between the groups
were all signiﬁcantly different (Po10 10, w2-test). Quantitative
reverse transcription–PCR analysis validated all the tested
upregulated genes in an extended cohort of 6 responders
compared with 10 patients with stable disease (Fig. 6c and
Supplementary Fig. 7 and Fig. 8).
Finally, we explored the effect of time on methylation status in
the same samples by using the enhanced reduced-representation
bisulﬁte sequencing assay (Fig. 7). Differentially methylated
regions (DMRs) between the two time points were deﬁned by a
more than 25% change in methylation and a false discovery rate
(FDR) r10%. Differential methylation was detected almost
exclusively in the three responding patients (Fig. 7b,d,e).
The number of DMRs remained low in non-responding patients
with a stable disease under therapy (Fig. 7a,c,e) and no change
was identiﬁed in untreated patients (Table 1, Supplementary
Fig. 9 and Supplementary Data 5). Changes observed in
responding patients were predominantly demethylation, whereas
changes detected in treated patients with a stable disease included
both gains and losses of DNA methylation (Supplementary
Fig. 9). In responders, DMRs were signiﬁcantly depleted in
promoters and in CpG islands while being enriched in generic
enhancers (Supplementary Fig. 10). Some overlap was detected
between DMRs and changes in gene expression in responders,
which was not observed in non-responders (Fig. 8).
Discussion
This ﬁrst comprehensive analysis of genetic alterations in CMML
cells demonstrates that azanucleosides, although inducing
dramatic changes in DNA methylation and gene expression in
responding patients, do not reduce the mutated allele burden, nor
permit the re-expansion of wild-type haematopoietic cells.
Previous screening of candidate genes identiﬁed somatic
mutations in TET2, ASXL1 and SRSF2 genes as the most frequent
recurrent events in CMML cells4. Our comprehensive analysis
validates this molecular ﬁngerprint and identiﬁes additional
recurrent abnormalities that may contribute to the disease
phenotype heterogeneity. Several of the most recurrent
mutations identiﬁed in leukaemic cells were associated with
age-related clonal haematopoiesis33–35 or ‘silent’ pre-leukaemic
clones36–38. The bias in myeloid differentiation towards the
granulomonocytic lineage that characterizes CMML could be
related to the expansion of such a clone, for example, due to early
clonal dominance of TET2 (refs 4,39). In this setting, the
occurrence of an additional mutation resulting in a stringent
arrest of differentiation leads to acute-phase disease38,40, as
illustrated by sequential analyses in UPN34 who partially
responded to decitabine for 2 years until the emergence of an
EZH2/ETV6 mutated subclone and an acute leukaemia
phenotype. Importantly, this observation indicates that the



























































































































Figure 4 | Serial whole-exome sequencing analysis of somatic variants.WES of sorted peripheral blood monocyte DNA was performed two- to ﬁvefold in
17 patients at a mean interval of 14±8 months (range: 4–32). The clonal evolution of recurrently mutated genes is shown. UPN indicates the patient
number. A selection of the variants detected by the ﬁrst whole-exome sequencing is shown (all the variants identiﬁed in each individual patient are depicted
in Supplementary Fig. 5). All the changes in variant allele frequency and new variants detected by repeating whole-exome sequencing are shown. Black
indicates the founding clone and subsequent subclones are shown in violet, red, orange, and green, successively. Patients were either untreated (a) or
treated with either azacytidine (AZA) or decitabine (DAC) as indicated in red. Blue dash lines indicate WES. (b) Patients with a stable disease on therapy.
(c) Responding patients.
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Figure 5 | Serial whole-genome sequencing in a 5-AZA exceptional responder.WGS was performed before 5-azatidine treatment (baseline), in complete
response (remission) and at disease progression (relapse). (a,b) Scatter plot of somatic variants identiﬁed at baseline, remission, and progression.
Chromosomal location is color coded and the size of the object denotes its predicted impact on protein function. High impact variants are those that are
predicted to have the highest likelihood of altering protein expression or function such as frameshifts or nonsense variants. Circles denote single-nucleotide
variants and triangles denote insertions or deletions. (c,d) Scatter plot of all variants identiﬁed with Freebayes at baseline, remission, and progression.
Chromosomal location is color coded. (e) Copy number changes as identiﬁed from whole-genome sequencing data using Sequenza.
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response to a hypomethylating agent does not prevent the
accumulation of genetic damage in the leukaemic clone.
The number of genetic alterations identiﬁed in the genome of
CMML cells was close to that observed in other haematological
malignancies26. Most somatic variants identiﬁed were transitions,
with a predominance of C:G-4T:A, and a mutational signature
suggesting that the historical mutational process was
related mostly to ageing26. Accordingly, the number of variants
identiﬁed in juvenile CMML, another myeloproliferative
neoplasm/myelodysplastic disease that occurs in young
children, is much lower than that measured in CMML41.
Although these results do not exclude some cytotoxic effect of
azanucleosides, their epigenetic activity appears to play a
central role in restoring a more balanced haematopoiesis in the
30–40% of CMML patients who respond to these drugs17,18.
Immunophenotyping analyses already suggested that these drugs
could eliminate bulk blast cells without eradicating leukaemia
stem and progenitor cells in AML patients42 and did not
correct CD34þ cell immunophenotypic aberrancies in CMML
patients43. Mutations in epigenetic genes observed in almost
every CMML case lead to DNA hypermethylation44 and
epigenetically controlled changes in gene expression contribute


















































































** *** *** ** *** ** * **
Upstream regulators P value Predicted activation
Lipopolysaccharide 3.84 10–13
IFN-gamma 1.49 10–11
CD40 ligand 2.52 10–10 Activated
IL1 beta 1.03 10–9 Activated






Figure 6 | Evolution of gene expression pattern on hypomethylating agent therapy. Gene expression was analysed at two time points in sorted
peripheral blood monocytes from 9 chronic myelomonocytic leukaemia patients, including three untreated and six treated with either azacytidine or
decitabine. These cases were randomly selected in each group. Three treated patients remained stable on therapy (non-responders) whereas the three
others were responders. In treated patients, the ﬁrst sample was collected before treatment, the second one after at least 5 drug cycles and just before the
next cycle. Volcano plots of genes differentially expressed between these two time points are shown in non-responders (a) and in responders
(b). The name of the most differentially deregulated genes is indicated. No signiﬁcant change in gene expression was detected in untreated patients
analysed twice at an at least 5-month interval (see also Table 1). Each dot (N¼ 24,563) represents a gene; green dots, padjr0.05, orange dots, abs (log2
(fold change)) Z1 and red dots, padj r0.05 and abs(log2 (fold change)) Z1. (c) Quantitative reverse transcriptase–PCR validation of the differential
expression of 8 genes in 6 responders (3 studied by RNA sequencing in b and 3 additional cases) and 10 non-responders (3 studied by RNA sequencing in
a and 7 additional cases). Normalizer gene, RPL32. Similar results were obtained with two other normalizer genes, GUS and HPRT (Supplementary Fig. 8).
(d) Signiﬁcant changes in pathways detected by analysing RNA sequencing data with Ingenuity (www.ingenuity.com/products/ipa).
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to the disease phenotype, as demonstrated for transcription
intermediary factor-1g (TIF1g) gene whose epigenetic
downregulation was identiﬁed in a fraction of patients, and
whose deletion in the myeloid compartment induces a CMML
phenotype in the mouse45. Clinical response to hypomethylating
drugs is associated with a re-expression of this gene when
initially downregulated45, indicating that hypomethylating
drugs can suppress epigenetic changes that contribute to
the disease phenotype. This epigenetic effect could decrease the
competitiveness of the most mutated cells in the progenitor and
stem cell compartment4,40 but not the mutated allele burden in
the mature cell compartment. Also, although we have shown
before that the number of subclones in the immature
compartment was usually low in CMML patients, we cannot
rule out that an impact of treatment on clonal architecture in the
bone marrow participates to the generation of a more balanced
haematopoiesis.
Clinical trials have shown that 30–40% of CMML patients
respond to azanucleosides2,18. Since epigenetic changes were
observed only in responders, speciﬁc patterns of epigenetic
changes may be amenable to reversion by azanucleosides17.
We have shown that differentially methylated non-promoter
regions of DNA at baseline distinguished responders from
non-responders to decitabine46, whereas the pattern of somatic
mutations did not18. Some epigenetic patterns could also prevent
the activity of hypomethylating drugs by either decreasing the
expression of human nucleoside transporters and metabolic
enzymes needed for their activation such as cytidine and
deoxycytidine kinases and cytidine deaminase16,47 or increasing
the expression of genes encoding cytokines such as CXCL4 and
CXCL7 that, when released, could antagonize the drug effects46.
In two responding patients, prolonged administration of
azanucleosides, although improving haematopoiesis, did not
prevent the accumulation of genetic events, ultimately leading
to acute transformation, indicating that these drugs do not
prevent genetic evolution of the leukaemic clone. Further analyses
are needed to determine whether they could even promote such
genetic evolution.
The present ﬁndings have clinical implications. First,
prolonged administration of hypomethylating drugs may not
have any beneﬁt in CMML patients when haematological
improvement is not observed after a few cycles. Second, these
drugs could increase the survival of responding patients by
restoring a more balanced haematopoiesis, but they might not
prevent the occurrence of new genetic events leading to acute
transformation. Finally, better analysis of how these drugs
modulate the immunogenicity of mutated cells could lead to
combination of hypomethylating agents with immune checkpoint
blockers as nucleoside analogues render the cells more
immunogenic through inducing the expression of cancer testis
antigens48, promoting the demethylation of programmed
death-1 immune checkpoint molecule49, and inducing
retrovirus activation50,51, suggesting that an interaction of
epigenetic drugs and immunotherapeutic approaches52 might
be considered. Our results also raise the question on whether
epigenetic targeting molecules currently developed to treat
haematological malignancies53,54 will eradicate mutated cells or
erase the epigenetic consequences of these mutations, leading to
the transient restoration of a more balanced haematopoiesis.
Methods
Patients. Peripheral blood and bone marrow samples were collected on ethylene-
diaminetetraacetic acid from 245 patients with a CMML diagnosis according to the
World Health Organisation criteria1. When indicated, several peripheral blood
samples were collected sequentially from a given patient (Supplementary Fig. 1). We
initially performed WES in 49, WGS in 17 and validation of recurrent mutations by
deep sequencing in 180 cases. Serial WES were performed in 17 patients, including 6
untreated and 11 treated with either decitabine (N¼ 6; EudraCT 2008-000470-21
GFM trial; NCT01098084; https://www.clinicaltrials.gov/)18 or AZA (N¼ 5;
following the European Medicines Agency approval; EMEA/H/C/000978). Responses
were classiﬁed according to the International Working Group 2006 criteria31.
Patients with stable disease without haematological improvement remained treated
until progression17. When indicated, sequential RNA-Seq and DNA methylation
analysis46 were performed. In treated patients, samples were collected immediately
before the following drug cycle. All the procedures were approved by the institutional
board of Gustave Roussy and the ethical committee Ile de France 1, and written
informed consent was obtained from each patient. Data collected from French and
Japanese patients were analysed homogeneously. Patient characteristics are in
Supplementary Table 1, the ﬂow chart of analyses in Supplementary Fig. 1.
Cell sorting. Bone marrow (N¼ 9) or peripheral blood (N¼ 7) mononucleated cells
were separated on Fycoll-Hypaque. Peripheral blood CD14þ monocytes were sorted
with magnetic beads and the AutoMacs system (Miltenyi Biotech, Bergish Gladbach,
Germany)45. Control samples were peripheral blood CD3-positive T lymphocytes
sorted with the AutoMacs system or buccal mucosa cells (N¼ 3) or skin ﬁbroblasts
(N¼ 12). All the samples used in the validation cohort (N¼ 180) were sorted
peripheral blood CD14þ monocytes. DNA and RNA were extracted from cell
samples using commercial kits. Monocytes were sorted for DNA sequencing on the
basis of our previous analysis of CMML clonal architecture showing the growth
advantage to the most mutated cells4, and ﬂow cytometry analysis of peripheral
blood monocytes showing limited phenotypic alteration in the classical monocyte
population in patients treated with hypomethylating drugs, even though responders
have more intermediate and non-classical monocytes19. In one patient, bone marrow
mononucleated cells were used for serial WGS. TET2 and TET3 gene sequencing in
UPN22 were performed in single CD14þ cells sorted using C1 (Fluidigm) after
whole-genomic DNA ampliﬁcation.
Table 1 | Changes induced by hypomethylating agents in gene expression and DNA methylation.
Untreated Treated non-responders Treated responders
Number of patients 3 3 3
Time between analyses (months) mean±s.d. 17±10 9±3 27±17
Changes in gene expression
Up 0 12 343
Down 0 51 170
Total 0 63 513
Differentially methylated regions
Up 0 28 19
Down 1 75 35,895
Total 0 103 35,914
Genomic analyses were performed at two time points in sorted peripheral blood monocytes of nine chronic myelomonocytic leukaemia patients, including three left untreated and six patients treated with
either azacytidine or decitabine. Among treated patients, 3 had a stable disease under therapy (non-responders) and three demonstrated clinical response (Figs 4 and 5). The ﬁrst sample was collected
before treatment, the second after at least ﬁve cycles of either azacytidine or decitabine, just before the next cycle. We measured the number of differentially expressed genes having abs(log2 (fold
change)) Z1 between T1 and T2, and the number of differentially methylated regions having Z25% difference between T1 and T2.
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Figure 7 | Evolution of DNA methylation pattern on hypomethylating drug therapy. Methylation was analysed at two time points in sorted monocytes
from nine chronic myelomonocytic leukaemia patients, including three untreated and six treated with either azacytidine or decitabine. Three treated patients
remained stable on therapy (non-responders) whereas the three others were responders. In treated patients, the ﬁrst sample was collected before treatment,
the second one after at least ﬁve drug cycles and just before the next cycle. (a,b) Chromosome ideograms representing differentially methylated regions
(DMRs) in non-responders (a) and in responders (b) are shown. Reduction in DNA methylation is in green, whereas increased methylation is in pink. (c,d)
Barplots showing the percentage of genomic regions with signiﬁcant changes in DNA methylation in non-responders (c) and in responders (d) are also shown.
No change was identiﬁed in the 3 untreated patients (Table 1). (e) Violin plots showing the evolution of global methylation change in each patient (untreated
patients in grey, treated with a stable disease (non-responders) in blue, treated responders in red with the lighter color indicating the earliest analysis.
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Functional analysis of mutated TET3. pcDNA3.1-TET3R1548H was generated
using Q5 site-directed mutageneis (New England Biolabs Evry, France) before
transfecting HEK293T cells with constructs encoding wild-type or mutated TET3.
After 2 days in culture, DNA was extracted and 5-hydroxymethylcytosine was
detected as previously described39.
Whole-exome sequencing. We performed WES in 49 patients at diagnosis. In 17
of them, 2–5 serial analyses were done. 1mg of genomic DNA was sheared with the
Covaris S2 system (LGC Genomics, Molsheim, France). DNA fragments were
end-repaired, extended with an ‘A’ base on the 30-end, ligated with paired-end
adaptors and ampliﬁed (six cycles) using a Bravo automated platform (Agilent
technologies). Exome-containing adaptor-ligated libraries were hybridized for 24 h
with biotinylated oligo RNA baits, and enriched with streptavidin-conjugated
magnetic beads using SureSelect (Agilent technologies, Les Ulis, France). The ﬁnal
libraries were indexed, pooled and paired-ends (2 100 bp) sequenced on Illumina
HiSeq 2000 (San Diego, CA). In nine cases, WES was performed in Japan following a
previously described protocol55. The mean coverage in the targeted regions was
112 (Supplementary Table 2). Two individual cases have been reported in
our previous studies4,8. Sequencing data are deposited at the European
Genome–Phenome Archive (EGA), hosted by the European Bioinformatics Institute
(EBI), under the accession number EGAS00001001264.
WES analysis. Raw reads were aligned to the reference human genome hg19
(Genome Reference Consortium GRCh37) using BWA 0.5.9 (Burrows–Wheeler
Aligner) backtrack algorithm with default parameters. PCR duplicates were removed
with Picard (http://picard.sourceforge.net) version 1.76. Local realignment around
indels and base quality score recalibration were performed using GATK 2.0.39
(Genome Analysis ToolKit). Statistics on alignment and coverage are given in
Supplementary Table 2. SNVs and indels were called with VarScan2 somatic 2.3.2
(ref. 56). Reads and bases with a Phred-based quality score r20 were ignored.
Variants with somatic P value below 10 4 (or 10 3 for samples with mean coverage
o100 or contamination 415% in CD3þ control sample) were reported. In
addition to the Fisher’s exact test of VarScan, we required (variant allele frequency in
the tumour sample–variant allele frequency in the normal sample) Z15% to dis-
tinguish somatic from germline variations. Variants were annotated with Annovar.
Mutations were searched in 1000G (April 2012) and Exome Sequencing Project
(ESP5400). Conservation of the position was predicted by PhyloP and the effect of
the mutation was predicted by SIFT, Polyphen2, LRT and MutationTaster. We
excluded variants reported in dbSNP version 129, ﬁltered variants located in
intergenic, intronic, untranslated regions and non-coding RNA regions, and
removed synonymous SNVs and variants with mapping ambiguities. A mutation
was reported as present if variant allele frequency (VAF) Z4%.
Targeted deep sequencing. Regarding exome validation, Ion AmpliSeq Custom
Panel Primer Pools were used to perform multiplex PCR for preparation of amplicon
libraries. Brieﬂy, 20 ng of DNA per primer pool quantiﬁed using a Qubit Fluo-
rometer (Invitrogen, Carlsbad, CA) were used in the multiplex PCR. Unique indexed
libraries per sample were generated, quantiﬁed by Qubit, pooled and run on an Ion
318 Chip using the Ion PGM Sequencer (Life Technologies). Seventy one per cent of
the candidates for somatic mutation were conﬁrmed by deep resequencing at a mean
coverage of 759 . In total, we validated 680 somatic mutations (Supplementary
Table 3). Also, the whole coding regions of genes found mutated in at least two
patients and expressed in myeloid cells were deep sequenced (mean coverage,
690 ) in a cohort of 180 CMML patients (Supplementary Table 4 and Table 5).
Ion AmpliSeq Custom Panel Primer Pools were used (10ng of genomic DNA per
primer pool) to perform multiplex PCR. Libraries were generated with addition of
paired-end adaptors (NEXTﬂex, Bioo Scientiﬁc) before paired-end sequencing
(2 150 bp reads) using an Illumina MiSeq ﬂow cell and the onboard cluster
method (Illumina, San Diego, CA). Quality of reads was evaluated using FastQC
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/). Raw reads were ﬁltered
with Trimommatic 0.30 (ref. 57) to remove adaptors, truncate any read whose
average quality on a sliding window (six bases) was r20, remove the start and the
end of a read if r20 and any read with an average quality r20 or a length o36.
Statistics on alignment and coverage are given in Supplementary Table 2 and
detailed analysis of each studied variant in Supplementary Table 3. Targeted
resequencing was analysed similarly to WES except the suppression of PCR
duplicates. We added the following public databases: ESP 6500, dbSNP 138,
COSMIC 68 (Catalogue Of Somatic Mutations In Cancer) and ClinVar (20140303).
Prediction of driver genes. We applied DrGaP (driver genes and pathways)58 to
synonymous and nonsynonymous somatic variants (889 in 694 genes) to measure
the probability of each variant to occur by chance. Among the 22 genes with FDR
r10%, 20 were mutated in at least 2 patients and actively transcribed in myeloid
cells (MIER and FIBIN genes carried 2 variants in a unique patient, respectively).
Six of the 26 recurrently mutated and actively transcribed genes were mutated in
only 2 patients: SH2B3 (FDR¼ 0.22), PHF6 (FDR¼ 0.22), DOCK2 (FDR¼ 0.30),
ABCC9 (FDR¼ 0.36), HUWE1 (FDR¼ 0.78) and TTN (FDR¼ 0.88).
Whole-genome sequencing. We performed WGS in 17 patients at diagnosis,
including one already studied by WES. Genomic DNA (1 mg) was sheared to
300–600 bp (average size¼ 398±14 bp) using a Covaris E210 (Covaris, Woburn,
Massachusetts, USA). Libraries for 101 bp paired-end sequencing were prepared
according to the Truseq PCR free protocol (Illumina). Library quality was
evaluated by quantitative PCR for quantiﬁcation (Kapa Biosystems Ltd., London,
UK) and by low output sequencing on Miseq (Illumina) for clusterisation efﬁ-
ciency. Samples were loaded on HiSeq 2000 and sequenced. Quality of reads was
evaluated using FastQC. Sequences were ﬁltered with Trimommatic. Reads were
aligned to the reference genome hg19 using BWA MEM algorithm 0.7.5a with
default parameters. The PCR duplicates were removed with Picard 1.94. Local
realignment and base quality score recalibration were performed using GATK
2.7.4. The mean coverage of all the samples was 31 . Detailed statistics on
alignment and coverage are given in Supplementary Table 6. Somatic SNVs were
identiﬁed by SomaticSniper 1.0.3 (ref. 59), VarScan2 2.3.7 and Strelka 1.0.14
(ref. 60). We conserved somatic variants withZ15 in normal,Z6 in tumour
and Z3 reads supporting the variant. We used a SomaticScore Tumour Z30 for
SomaticSniper, a Somatic P valuer0.01 for VarScan2 and a QSS_N/QSI_NTZ15
for Strelka. We ran Strelka with the following parameters: ssnvNoise¼
0.000000005, sindelNoise¼ 0.00000001, ssnvPrior¼ 0.001, sindelPrior¼ 0.001 and
extraStrelkaArguments: -used-allele-count-min-qscore 20 and min-qscore 20. The
other parameters were set by default. We removed SNVs annotated as SpanDel,
BCNoise or DP in FILTER ﬁeld. We excluded INDELs reported as OVERLAP or
deﬁned as Repeat, iHpol, BCNoise or DP in the FILTER ﬁeld. In addition, we
required (variant allele frequency in the tumour sample–variant allele frequency in
the normal sample)Z20% and excluded the variants whose allele frequency in the
normal sample was Z15% to differentiate somatic from germline mutations.
We removed the variants located in low complexity regions, immunoglobulin loci
(as reported in http://www.genecards.org/ for TCRA, TCRB, TCRG, IGH, IGL
and IGK) and genes in which false positives have been frequently detected by
new-generation sequencing61. By removing low complexity regions, as
deﬁned in the masked genome chromOut.tar.gz generated by repeatMasker
(http://hgdownload.soe.ucsc.edu/goldenPath/hg19/bigZips/), we removed 45% of
the genome, thereby eliminating 74, 69 and 71% of the SNVs detected by using
SomaticSniper, VarScan2 and Strelka, respectively, and 87 and 77% of the indels
identiﬁed by VarScan2 and Strelka, respectively. In subsequent analyses, the SNVs
and indels identiﬁed by combining these stringent algorithms were used.
Sequencing data are deposited at the EGA hosted by the EBI under the accession
number EGAS00001001264.
Potential hotspots in promoters and enhancers. First, sequential windows were
used to calculate the probability for a 250-bp region to carry at least two variants in
two distinct patients among 17 patients. The probability to ﬁnd at least 2 mutations
in one of the 6.82 106 windows of 250 bp deﬁned in non-repeated regions of the
genome among 17 patients was 10 3. Second, we deﬁned a potential hotspot
region as a region in which, in a sequence shorter than 250 bp, two variants were
identiﬁed in at least two patients. With that method, from the 8,077 variants
detected (Supplementary Data 2), we identiﬁed 21 clusters of variants on a same
chromosome at most 250 bp far, deﬁning potential hotspots (Supplementary
Data 3). We detected 147 variants in 144 distinct promoter regions (from
 2,000 bp before to þ 200 bp after the translation starting site obtained from
UCSC website on 07 November 2014) and 37 variants in the 43,011 enhancer
regions reported in ref. 30, of which three were located in the 3,795 enhancers
whose activity is Z5% in blood and Z5% in monocytes.










Figure 8 | Relationship between changes in DNA methylation and in gene
expression. Venn diagrams of interactions between differentially
methylated regions (DMR, red circles) and differentially expressed genes
(upregulated in blue; downregulated in green) as deﬁned in Fig. 5 (padj
r0.05 and abs(log2 (fold change)) Z1).
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Independent case report from Lee Mofﬁtt Cancer Center. A 57-year-old female
patient progressedB10 months after diagnosis of a type-1 CMML according to the
World Health Organization deﬁnition with normal cytogenetics, prompting the
initiation of 5-azacitidine therapy. After four cycles of therapy, the patient had a
complete remission that persisted for 30 cycles. Disease progression was suspected
because of a declining platelet count and conﬁrmed by an increase in bone marrow
myeloblasts. 5-azacitidine was discontinued and the patient transformed to AML
8 months later. Bone marrow mononucleated cells32 were collected before the
treatment start, during complete response and at progression. The following part of
the study was approved by the H. Lee Mofﬁtt Cancer Center institutional review
boards and the patient provided informed consent before initiating sequencing
procedures under the Total Cancer Care protocol. WGS was performed on ﬁve
lanes for each leukaemia sample, and two lanes for the CD3þ germline on the
Illumina HiSeq X platform. The goal was to achieve 125 and 60 depth,
respectively. Sequencing data was aligned to b37d5 reference genome with BWA
MEM, and duplicates were marked, and multiple lanes merged using novosort.
Somatic SNV and INDEL variant calling was performed using Strelka for tumour
normal pairs. Somatic copy number variants, loss of heterozygosity regions, ploidy
and purity were determined using Sequenza. Freebayes with minimum VAF¼ 0.01
was used to generate variants from individual samples, and to assess the number of
clones. Variants were annotated using Variant Effect Predictor. Phylosub was used
to reconstruct the evolutionary lineage of samples, using either high, or medium-
and high-impact variants (loss of function vs missense, respectively).
RNA sequencing. Sequential RNA-Seq was performed on 18 samples (9 patients)
with high-quality RNA (RNA Integrity Score Z7.0 as determined by the Agilent
2100 Bioanalyzer). RNA was quantiﬁed using a Qubit Fluorometer (Invitrogen,
Cergy-Pontoise, France). RNA-Seq libraries were prepared using the SureSelect
Automated Strand Speciﬁc RNA Library Preparation Kit as per manufacturer’s
instructions (Agilent technologies) and a Bravo automated platform (Houston,
TX). Brieﬂy, 150 ng of total RNA sample was used for poly-A mRNA selection
using oligo(dT) beads and subjected to thermal mRNA fragmentation. The
fragmented mRNA samples were subjected to complementary DNA synthesis and
further converted into double stranded DNA that was used for library preparation.
The ﬁnal libraries were bar-coded, puriﬁed, pooled together in equal concentra-
tions and subjected to paired-end (101 bp) sequencing on HiSeq2000 (San Diego,
CA). Two separate samples were multiplexed into each lane. Quality of reads was
evaluated using FastQC.
RNA-Seq analysis. Sequences were ﬁltered with Trimommatic and alignment was
performed with Tophat2 version 2.0.9 (ref. 62) and Bowtie2 version 2.1.0 (ref. 63).
The ﬁltered reads were aligned to a reference transcriptome (downloaded from UCSC
website on 20 December 2013). The remaining reads were split and segments were
aligned on the reference genome, as described62. In average, 88.95% of reads were aligned
(Supplementary Table 9) and counted with HTSeq (v0.5.4p5) (ref. 64) using the following
parameters: --mode¼ intersection-nonempty --minaqual¼ 20 --stranded¼ no.
Differential expression analysis was performed using DESeq2 package version 1.6.3
(ref. 65) with R statistical software version 3.1.2. To study the effect of time in each of the
three groups (Supplementary Data 4), we used a generalized linear model to explain the
counting Yi: YiBGroup:PatientþTimeþGroupþGroup:Time where Group indicates
the status (untreated, responders and stable disease). We used independent ﬁltering to
set aside genes that have no or little chance to be detected as differentially expressed.
To test the effect of time in each group, we used three contrasts deﬁned as linear
combinations of factor level means. Validation of RNA-Seq data was performed by
quantitative PCR analysis in a selection of eight genes, using three independent genes
as reporters (Supplementary Fig. 8).
Genome-wide DNA methylation by ERRBS. Twenty-ﬁve nanograms of
high-molecular weight genomic DNA were used to perform the ERRBS assay as
previously described66 and sequenced on a HiSeq2000 Illumina sequencer. 50 bp
reads were aligned against a bisulﬁte-converted human genome (hg19) using
Bowtie and Bismark67. Downstream analysis was performed using R version 3.0.3,
Bioconductor 2.13 and the MethylSig 0.1.3 package. Only genomic regions with
coverage between 10 and 500 were used for the downstream analysis
(Supplementary Data 5). DMR were identiﬁed by ﬁrst summarizing the
methylation status of genomic regions into 25-bp tiles and then identifying regions
with absolute methylation difference Z25% and FDR o10%. DMRs were
annotated to the RefSeq genes using the following criteria: (i) DMRs overlapping
with a gene were annotated to that gene, (ii) intergenic DMRs were annotated to all
neighbouring genes within a 50-kb window, and (iii) if no gene was detected within
a 50-kb window, then the DMR was annotated to the nearest TSS.
References
1. Vardiman, J. W. et al. The 2008 revision of the World Health Organization
(WHO) classiﬁcation of myeloid neoplasms and acute leukemia: rationale and
important changes. Blood 114, 937–951 (2009).
2. Padron, E. & Steensma, D. P. Cutting the cord from myelodysplastic
syndromes: chronic myelomonocytic leukemia-speciﬁc biology and
management strategies. Curr. Opin. Hematol. 22, 163–170 (2015).
3. Jankowska, A. M. et al. Mutational spectrum analysis of chronic
myelomonocytic leukemia includes genes associated with epigenetic regulation:
UTX, EZH2, and DNMT3A. Blood 118, 3932–3941 (2011).
4. Itzykson, R. et al. Clonal architecture of chronic myelomonocytic leukemias.
Blood 121, 2186–2198 (2013).
5. Kon, A. et al. Recurrent mutations in multiple components of the cohesin
complex in myeloid neoplasms. Nat. Genet. 45, 1232–1237 (2013).
6. Yoshida, K. et al. Frequent pathway mutations of splicing machinery in
myelodysplasia. Nature 478, 64–69 (2011).
7. Gelsi-Boyer, V. et al. Genome proﬁling of chronic myelomonocytic leukemia:
frequent alterations of RAS and RUNX1 genes. BMC Cancer 8, 299 (2008).
8. Kosmider, O. et al.Mutation of the colony-stimulating factor-3 receptor gene is
a rare event with poor prognosis in chronic myelomonocytic leukemia.
Leukemia 27, 1946–1949 (2013).
9. Dunbar, A. J. et al. 250K single nucleotide polymorphism array karyotyping
identiﬁes acquired uniparental disomy and homozygous mutations, including
novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 68,
10349–10357 (2008).
10. Go´mez-Seguı´, I. et al. Novel recurrent mutations in the RAS-like GTP-binding
gene RIT1 in myeloid malignancies. Leukemia 27, 1943–1946 (2013).
11. Klinakis, A. et al. A novel tumour-suppressor function for the Notch pathway
in myeloid leukaemia. Nature 473, 230–233 (2011).
12. Singh, H. et al. Putative RNA-splicing gene LUC7L2 on 7q34 represents a
candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J. 3,
e117 (2013).
13. Gambacorti-Passerini, C. B. et al. Recurrent ETNK1 mutations in atypical
chronic myeloid leukemia. Blood 125, 499–503 (2015).
14. Itzykson, R. et al. Prognostic score including gene mutations in chronic
myelomonocytic leukemia. J. Clin. Oncol. 31, 2428–2436 (2013).
15. Patnaik, M. M. et al. ASXL1 and SETBP1 mutations and their prognostic
contribution in chronic myelomonocytic leukemia: a two-center study of 466
patients. Leukemia 28, 2206–2212 (2014).
16. Navada, S. C., Steinmann, J., Lu¨bbert, M. & Silverman, L. R. Clinical
development of demethylating agents in hematology. J. Clin. Invest. 124, 40–46
(2014).
17. Tsai, H. C. et al. Transient low doses of DNA-demethylating agents exert
durable antitumor effects on hematological and epithelial tumor cells. Cancer
Cell 21, 430–446 (2012).
18. Braun, T. et al. Molecular predictors of response to decitabine in advanced
chronic myelomonocytic leukemia: a phase 2 trial. Blood 118, 3824–3831 (2011).
19. Selimoglu-Buet, D. et al. Characteristic repartition of monocyte subsets
as a diagnostic signature of chronic myelomonocytic leukemia. Blood 125,
3618–3626 (2015).
20. Hinson, J. T. et al. Titin mutations in iPS cells deﬁne sarcomere insufﬁciency as
a cause of dilated cardiomyopathy. Science 349, 982–986 (2015).
21. Quesada, V. et al. Exome sequencing identiﬁes recurrent mutations of the
splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44,
47–52 (2011).
22. Palomero, T. et al. Recurrent mutations in epigenetic regulators, RHOA and
FYN kinase in peripheral T cell lymphomas. Nat. Genet. 46, 166–170 (2014).
23. Abdel-Wahab, O. et al. Genetic characterization of TET1, TET2, and TET3
alterations in myeloid malignancies. Blood 114, 144–147 (2009).
24. Ko, M. et al. TET proteins and 5-methylcytosine oxidation in hematological
cancers. Immunol. Rev. 263, 6–21 (2015).
25. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M.
R. Deciphering signatures of mutational processes operative in human cancer.
Cell Rep. 3, 246–259 (2013).
26. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer.
Nature 500, 415–421 (2013).
27. Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma.
Science 339, 959–961 (2013).
28. Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identiﬁes
new mutational signatures and potential therapeutic targets. Nat. Genet. 47,
505–511 (2015).
29. Melton, C., Reuter, J. A., Spacek, D. V. & Snyder, M. Recurrent somatic
mutations in regulatory regions of human cancer genomes. Nat. Genet. 47,
710–716 (2015).
30. Andersson, R. et al. An atlas of active enhancers across human cell types and
tissues. Nature 507, 455–461 (2014).
31. Cheson, B. D. et al. Clinical application and proposal for modiﬁcation of the
International Working Group (IWG) response criteria in myelodysplasia. Blood
108, 419–425 (2006).
32. Mohamedali, A. M. et al. High concordance of genomic and cytogenetic
aberrations between peripheral blood and bone marrow in myelodysplastic
syndrome (MDS). Leukemia 29, 1928–1938 (2015).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10767
12 NATURE COMMUNICATIONS | 7:x | DOI: 10.1038/ncomms10767 | www.nature.com/naturecommunications
33. Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse
outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
34. Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from
blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).
35. Xie, M. et al. Age-related mutations associated with clonal hematopoietic
expansion and malignancies. Nat. Med. 20, 1472–1478 (2014).
36. Jan, M. et al. Clonal evolution of preleukemic hematopoietic stem cells precedes
human acute myeloid leukemia 4. Sci. Transl. Med. 20, 149ra118 (2012).
37. Shlush, L. I. et al. Identiﬁcation of pre-leukaemic haematopoietic stem cells in
acute leukaemia. Nature 506, 328–333 (2014).
38. Potter, N. E. & Greaves, M. Cancer: Persistence of leukaemic ancestors. Nature
506, 300–301 (2014).
39. Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic
abnormalities in mouse and is a recurrent event during human
lymphomagenesis. Cancer Cell 20, 25–38 (2011).
40. Itzykson, R. & Solary, E. An evolutionary perspective on chronic
myelomonocytic leukemia. Leukemia 27, 1441–1450 (2013).
41. Sakaguchi, H. et al. Exome sequencing identiﬁes secondary mutations of
SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat. Genet. 45,
937–941 (2013).
42. Craddock, C. et al. Azacitidine fails to eradicate leukemic stem/progenitor cell
populations in patients with acute myeloid leukemia and myelodysplasia.
Leukemia 27, 1028–1036 (2013).
43. Shen, Q. et al. Flow cytometry immunophenotypic ﬁndings in chronic
myelomonocytic leukemia and its utility in monitoring treatment response.
Eur. J. Haematol. 95, 168–176 (2015).
44. Figueroa, M. E. et al. MDS and secondary AML display unique patterns and
abundance of aberrant DNA methylation. Blood 114, 3448–3458 (2009).
45. Aucagne, R. et al. Transcription intermediary factor 1g is a tumor suppressor in
mouse and human chronic myelomonocytic leukemia. J. Clin. Invest. 121,
2361–2370 (2011).
46. Meldi, K. et al. Speciﬁc molecular signatures predict decitabine response in
chronic myelomonocytic leukemia. J. Clin. Invest. 125, 1857–1872 (2015).
47. Treppendahl, M. B., Kristensen, L. S. & Grønbæk, K. Predicting response to
epigenetic therapy. J. Clin. Invest. 124, 47–55 (2014).
48. Goodyear, O. et al. Induction of a CD8þ T-cell response to the MAGE
cancer testis antigen by combined treatment with azacitidine and sodium
valproate in patients with acute myeloid leukemia and myelodysplasia. Blood
116, 1908–1918 (2010).
49. Yang, H. et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in
myelodysplastic syndromes is enhanced by treatment with hypomethylating
agents. Leukemia 28, 1280–1288 (2014).
50. Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by
inducing viral mimicry by endogenous transcripts. Cell 162, 961–973 (2015).
51. Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon
response in cancer via dsRNA including endogenous retroviruses. Cell 162,
974–986 (2015).
52. Licht, J. D. DNA methylation inhibitors in cancer therapy: the immunity
dimension. Cell 162, 938–939 (2015).
53. Montenegro, M. F. et al. Targeting the epigenetic machinery of cancer cells.
Oncogene 34, 135–143 (2015).
54. Campbell, R. M. & Tummino, P. J. Cancer epigenetics drug discovery and
development: the challenge of hitting the mark. J. Clin. Invest. 124, 64–69
(2014).
55. Yoshida, K. et al. The landscape of somatic mutations in Down syndrome-
related myeloid disorders. Nat. Genet. 45, 1293–1299 (2013).
56. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration
discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012).
57. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a ﬂexible trimmer for
Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
58. Hua, X. et al. DrGaP: a powerful tool for identifying driver genes and pathways
in cancer sequencing studies. Am. J. Hum. Genet. 93, 439–451 (2013).
59. Larson, D. E. et al. SomaticSniper: identiﬁcation of somatic point mutations in
whole genome sequencing data. Bioinformatics 28, 311–317 (2012).
60. Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from
sequenced tumor-normal sample pairs. Bioinformatics 28, 1811–1817 (2012).
61. Fuentes Fajardo, K. V. et al. Detecting false-positive signals in exome
sequencing. Hum. Mutat. 33, 609–613 (2012).
62. Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of
insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
63. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat.
Methods 9, 357–359 (2012).
64. Anders, S., Pyl, P. T. & Huber, W. HTSeq–a Python framework to work with
high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
65. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
dispersion for RNA-Seq data with DESeq2. Genome Biol. 15, 550 (2014).
66. Park, Y., Figueroa, M. E., Rozek, L. S. & Sartor, M. A. MethylSig: a whole
genome DNA methylation analysis pipeline. Bioinformatics 30, 2414–2422
(2014).
67. Krueger, F. & Andrews, S. R. Bismark: a ﬂexible aligner and methylation caller
for Bisulﬁte-Seq applications. Bioinformatics 27, 1571–1572 (2011).
Acknowledgements
This programme was supported by grants from Ligue Nationale Contre le Cancer (e´quipe
labellise´e), Institut National du Cancer (INCa PLBIO, SIRIC SOCRATE), Institut
National du Cancer and Direction Ge´ne´rale de l’Offre de Soins (PHRC-K 2011-182),
Agence Nationale de la Recherche (Molecular Medicine in Oncology; Paris
Alliance Cancer Research Institute: France Ge´nomique National programs funded by
‘Investissements d’avenir’). J.M. was supported by the Fondation pour la Recherche
Me´dicale (FDT20140931007).
Author contributions
J.M., T.Q., V.G., M.D., M.J.C. and S.K. were involved in bioinformatics, N.D. in
all the molecular analyses, N.D., K.Y., N.P.-M. and S.O. in whole-exome sequencing,
N.D., V.M., F.A. and J.F.D. in whole-genome sequencing, N.D., E.C., D.A., S.S. and
D.S.-B. in RNA sequencing, M.R.S. and L.B.A. in mutational signature analysis, K.M.
and M.F. in whole-genome methylation, M.M. in patient sample manipulation and
cell sorting, P.F., T.B., R.I., S.d.B., B.Q., E.J., S.O. and E.P. provided clinical samples,
W.V., O.B., C.P. and E.P. discussed the results and provided advices, J.M., T.Q. and
N.D. designed the ﬁgures, E.S. designed the study, analysed the results and wrote
the manuscript.
Additional information
Accession codes: Whole-exome sequencing, whole-genome sequencing, RNA sequen-
cing and eRRBS raw sequence ﬁles (fastq ﬁles) have been deposited in the European
Genome-phenome Archive (EGA), under accession code https://www.ebi.ac.uk/ega/
studies/EGAS00001001264.
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Merlevede, J. et al. Mutation allele burden remains
unchanged in chronic myelomonocytic leukaemia responding to hypomethylating
agents. Nat. Commun. 7:10767 doi: 10.1038/ncomms10767 (2016).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10767 ARTICLE
NATURE COMMUNICATIONS | 7:x | DOI: 10.1038/ncomms10767 | www.nature.com/naturecommunications 13
